Tumor Necrosis Factor Inhibitors

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

Adults have a decreased risk for developing autoimmune thyroid disease after being diagnosed with rheumatoid arthritis, with the risk even lower for those receiving disease-modifying antirheumatic drugs, according to study data.

SAN DIEGO — Rheumatology research still offers too few head-to-head clinical trials of biologic medications to help clinicians manage rheumatoid arthritis, according to data presented at the 2023 Congress of Clinical Rheumatology West.

Patient-reported outcomes in individuals with psoriatic arthritis receiving either ustekinumab or TNF inhibitors were “generally comparable” after 3 years of follow-up, according to data published in Arthritis Research & Therapy.

Patients with rheumatoid arthritis who receive TNF inhibitors are more likely to develop psoriasis vs. those treated with methotrexate, according to an analysis of more than 880,000 post-marketing reports published in Scientific Reports.

Age, disease duration and sex are factors that may predict how likely a patient with psoriatic arthritis may be to enter remission following therapy with a TNF inhibitor, according to data published in Rheumatology.

The American College of Rheumatology “strongly recommends” against the use of glucocorticoids as a first-line therapy for interstitial lung disease in patients with systemic sclerosis-associated ILD, according to newly released guidelines.